Semergen - Medicina De Familia 

About: Semergen - Medicina De Familia is an academic journal published by Elsevier BV. The journal publishes majorly in the area(s): Medicine & Internal medicine. It has an ISSN identifier of 1138-3593. Over the lifetime, 3024 publications have been published receiving 7085 citations. The journal is also known as: Medicina de familia SEMERGEN & Sociedad Española de Medicina Rural y Generalista (Ed. impresa).

Guías en el manejo de la hipertensión

Abstract: In the last year, several scientific societies have published guidelines for the management of arterial hypertension. In Spain, two clinical practice guidelines have had a strong impact and have been closely followed in the last few years: the first is the Guideline of the National Heart, Lung and Blood Institute, although their last report (JNC 7) was published in 2003; the second is the clinical practice guideline for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), whose latest version was published in 2007, although an update was published in 2009. A new ESC/ESH document, published in 2013, adopts a mainly educational stance, closely rooted in clinical practice. Many of the recommendations maintain the same criteria as previous guidelines. However, the new publication shows greater rigor and contains major contributions such as specification of the level of evidence and grade of recommendation for each recommendation, which was lacking in the previous guidelines of these societies. The document is both practical and easy to consult, consisting of 17 tables, 5 figures and 18 blocks of recommendations. The JNC 8 report, however, has a single objective: to respond to three questions that are considered a priority and which refer exclusively to drug therapy. Nine recommendations are made relating to these three questions.

CDC guidelines for prescribing opioids for chronic pain

Abstract: Disease Control and Prevention (CDC), the use of antibiotics is the single most important modifiable driver leading to antibiotic resistance around the world. Despite being among the most commonly prescribed medications, up to 50 percent of antibiotics are not needed or are not prescribed for optimal efficacy. In the United States, each year at least two million people are infected with antibiotic resistant bacteria and at least 23,000 people die as a result of these infections.1 Antibiotic resistant infections lead to higher health care costs, poor health outcomes and more challenging treatment regimens.2

Guías en el manejo de la dislipemia

Abstract: The AHA/ACC 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease (ASCVD) in adults contains major differences with the previous ESC/EAS 2011 guidelines and the remaining international guidelines, which has generated major controversies. The AHA/ACC document has developed a new model for estimating cardiovascular risk for primary prevention which is not comparable with the SCORE recommended in the European guidelines. This guideline does not establish a fixed target for low-density lipoprotein cholesterol (LDLc). Instead, it identifies 4 major statin benefit groups at risk for the development ASCVD, who should receive low-, moderate-, and high-intensity statin therapy to reduce LCLc. In contrast, the European guidelines maintain LDLc as the main treatment target and non-high-density lipoprotein cholesterol as a secondary treatment target. The document recommends calculating cardiovascular risk for the overall treatment of patients with dyslipidemia according to 4 risk levels (low, moderate, high, and very high), establishes LDLc treatment targets, and recommends a statin-based therapeutic strategy and other, lipid-lowering strategies, aimed at achieving these targets. The American guidelines cannot be extrapolated to the European population. Target-based treatment, as recommended in the EAS/ESC guidelines, is the best strategy for Europe. In Spain, the Primary Care Guidelines of the Spanish Society of Family and Community Medicine (semFYC) and the Spanish Society of Primary Care Physicians (SEMERGEN) are based on the European recommendations. Finally, the Spanish Society of Arteriosclerosis (SEA), SEMERGEN, semFYC and the Spanish Society of General Medicine (SEMG) are reaching a consensus on the approach and management of patients with atherogenic dyslipidemia in primary care.

Validación de la escala de soledad de UCLA y perfil social en la población anciana que vive sola

Abstract: Resumen Introduccion Este articulo explora el fenomeno social creciente del anciano que vive solo, desde 2 vertientes: la soledad objetiva de vivir solo y la subjetiva de sentirse solo. Objetivo Validar la escala de soledad de UCLA como instrumento de medida global de la sensacion de soledad y conocer el perfil social en la poblacion anciana que vive sola. Metodologia Estudio observacional realizado durante 2 anos (2012-2013) para identificar la poblacion anciana que vive sola y estudio de casos y controles para la validacion de la escala de soledad de UCLA. La muestra fue realizada en 3 consultas de 2 centros de salud, del medio urbano y rural. Se estudio la validez de constructo, la validez discriminante y el analisis de sensibilidad. Resultados El 22,3% viven solos, el 61,7% por perdida del conyuge, con una edad media de 70,7 anos; el 82,7% son mujeres. El 17,3% carecen de vinculos familiares y el 63,2% se sienten solos. La escala de UCLA tiene una validez de constructo con altas correlaciones entre items; se confirma su validez discriminante respecto a los ancianos que no viven solos con un alfa de Cronbach de 0,95, y es un instrumento sensible al cambio. Conclusiones Uno de cada 4-5 ancianos viven solos, fundamentalmente por la perdida del conyuge; las mujeres triplican a los hombres. Dos de cada 3 personas experimentan la sensacion de soledad. La escala de UCLA ha demostrado ser un instrumento util y sensible para medir el sentimiento de soledad en los ancianos.